Recently stock market analysts have updated their consensus ratings on shares of Avalanche Biotechnologies, Inc. (AAVL).

Most recent broker ratings

03/01/2016 – Avalanche Biotechnologies, Inc. had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 9 price target on the stock.

02/02/2016 – Avalanche Biotechnologies, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 12 price target on the stock.

01/07/2016 – Avalanche Biotechnologies, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 15 price target on the stock.

06/16/2015 – Avalanche Biotechnologies, Inc. was downgraded to “market perform” by analysts at William Blair. They now have a USD 24 price target on the stock.

06/16/2015 – Avalanche Biotechnologies, Inc. was downgraded to “neutral” by analysts at SunTrust. They now have a USD 25 price target on the stock.

06/16/2015 – Avalanche Biotechnologies, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 55 price target on the stock.

05/01/2015 – Avalanche Biotechnologies, Inc. had its “hold” rating reiterated by analysts at Zacks.

Avalanche Biotechnologies, Inc. has a 50 day moving average of 5.37 and a 200 day moving average of 6.78. The stock’s market capitalization is 88.43M, it has a 52-week low of 4.00 and a 52-week high of 41.60.

The share price of the company (AAVL) was down -14.29%, with a high of 4.83 during the day and the volume of Avalanche Biotechnologies, Inc. shares traded was 542078.

View other investors thoughts on Avalanche Biotechnologies, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.